USA flag logo/image

An Official Website of the United States Government

THE OBJECTIVE OF THIS PROPOSAL IS TO DEVELOP SENSITIVE, NONISOTOPIC…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
3359
Program Year/Program:
1985 / SBIR
Agency Tracking Number:
3359
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Lucitech Inc.
9635 Genesee Ave. #e2 San Diego, CA 92121
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1985
Title: THE OBJECTIVE OF THIS PROPOSAL IS TO DEVELOP SENSITIVE, NONISOTOPIC BIOLUMINESCENT LIGAND RECEPTOR ASSAYS FOR OXYTOCIN (OT) AND ARGININE-VASOPRESSIN (AVP).
Agency: HHS
Contract: N/A
Award Amount: $49,205.00
 

Abstract:

THE OBJECTIVE OF THIS PROPOSAL IS TO DEVELOP SENSITIVE, NONISOTOPIC BIOLUMINESCENT LIGAND RECEPTOR ASSAYS FOR OXYTOCIN (OT) AND ARGININE-VASOPRESSIN (AVP). OUR LABORATORY HAS DEVELOPED METHODS TO COVALENTLY BIND FIREFLY LUCIFERIN TO VARIOUS BIOLOGICALLY ACTIVE MOLECULES. UNDER THE APPROPRIATE CONDITIONS, THE LUCIFERIN-DERIVED MOLECULE RETAINS ITS BIOLOGIC FUNCTION AND ALSO HAS LUCIFERIN ACTIVITY (I.E., THE ABILITY TO PRODUCE PHOTONS OF LIGHT IN THE PRESENCE OF LUCIFERASE, MAGNESIUM, AND ATP). IN EFFECT, WE ARE ABLE TO ""LABEL'' VARIOUS MOLECULES, SUCH AS PROTEINS, PEPTIDES, AND STEROIDS WITH A NONRADIOACTIVE PROBE. THE LUCIFERIN-DERIVED MOLECULE MAY THEN BE USED IN BIOLUMINESCENT LIGAND RECEPTOR ASSAYS, ANALOGOUS TO RADIOLIGAND RECEPTOR ASSAYS. BECAUSE OF THE SENSITIVITY OF THE LUCIFERIN-LUCIFERASE REACTION (MEASUREABLE LIGHT IS PRODUCED WITH 10 ATAMOLES OF LUCIFERIN) THESE ASSAYS ARE 5005000-FOLD MORE SENSITIVE THAN EXISTING ASSAYS USING 3H-LABELED COMPOUNDS. THIS INCREASED SENSITIVITY IS EXTREMELY IMPORTANT FOR THE LOCALIZATION AND CHARACTERIZATION OF SPECIFIC NEUROPEPTIDE RECEPTOR SITES IN DISCRETE BRAIN REGIONS. OT AND AVP NEURONS HAVE BEEN VISUALIZED IN MANY BRAIN REGIONS; HOWEVER, SPECIFIC BINDING SITES HAVE BEEN DIFFICULT TO LOCALIZE AND CHARACTERIZE DUE TO THE RELATIVELY LOW SPECIFIC ACTIVITY OF THE AVAILABLE RADIOLABELED LIGANDS. CONSEQUENTLY, THE INCREASED SENSITIVITY OF LUCIFERIN-DERIVED OT AND AVP WILL BE EXTREMELY IMPORTANT FOR THE LOCALIZATION AND CHARACTERIZATION OF SPECIFIC RECEPTOR SITES IN DISCRETE BRAIN REGIONS. THIS INFORMATION WILL BE VERY IMPORTANT IN FURTHER ELUCIDATION OF THE PHYSIOLOGICAL IMPORTANCE OF OT AND AVP IN BRAIN FUNCTION. THE SECOND GOAL OF THIS RESEARCH WILL BE TO DEVELOP LUCIFERIN ANALOGS WHICH MAY BE MORE READILY BOUND TO OTHER MOLECULES, ENABLING US TO MORE WIDELY UTILIZE LUCIFERIN-DERIVED COMPOUNDS AS AN ALTERNATIVE TO RADIOLABELED COMPOUNDS.

Principal Investigator:

James m. schaeffer
PRINCIPAL INVESTIGATOR
6194524213

Business Contact:

Small Business Information at Submission:

Lucitech Inc.
9635 Genesee Ave. #e2 San Diego, CA 92121

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No